Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Common Equity: 2020-2022

Historic Common Equity for Terns Pharmaceuticals (TERN) over the last 3 years, with Dec 2022 value amounting to $276.9 million.

  • Terns Pharmaceuticals' Common Equity rose 40.68% to $258.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $258.4 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of $276.9 million for FY2022, which is 72.76% up from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Common Equity of $276.9 million as of FY2022, which was up 72.76% from $160.3 million recorded in FY2021.
  • Over the past 5 years, Terns Pharmaceuticals' Common Equity peaked at $276.9 million during FY2022, and registered a low of -$117.4 million during FY2020.
  • For the 3-year period, Terns Pharmaceuticals' Common Equity averaged around $106.6 million, with its median value being $160.3 million (2021).
  • Data for Terns Pharmaceuticals' Common Equity shows a peak YoY spiked of 236.50% (in 2021) over the last 5 years.
  • Terns Pharmaceuticals' Common Equity (Yearly) stood at -$117.4 million in 2020, then skyrocketed by 236.50% to $160.3 million in 2021, then surged by 72.76% to $276.9 million in 2022.